Figure 6
From: ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
Bcl-2 and Bcl-xL are down-regulated in MDA-MB-231R cells and are unchanged in MDA-MB-231 cells following ABT-737 treatment. (A) The expression of Bcl-2 and Bcl-xL in MDA-MB-231R cells gradually decreased over 24 hours when treated with 1 μM of ABT-737. (B) In contrast, the expression of Bcl-2 and Bcl-xL in the MDA-MB-231 cells did not change after ABT-737 treatment.